生物
免疫系统
临床试验
信息和通信技术
免疫
免疫学
免疫检查点
免疫疗法
生物信息学
计算机科学
万维网
作者
Padmanee Sharma,Sangeeta Goswami,Deblina Raychaudhuri,Bilal A. Siddiqui,Pratishtha Singh,Ashwat Nagarajan,Jielin Liu,Sumit K. Subudhi,Candice C. Poon,Kristal L. Gant,Shelley M. Herbrich,Swetha Anandhan,Shajedul Islam,Moran Amit,Gayathri Anandappa,James P. Allison
出处
期刊:Cell
[Elsevier]
日期:2023-04-01
卷期号:186 (8): 1652-1669
被引量:264
标识
DOI:10.1016/j.cell.2023.03.006
摘要
Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer patients and conferred durable clinical benefits, including cure in a subset of patients. Varying response rates across tumor types and the need for predictive biomarkers to optimize patient selection to maximize efficacy and minimize toxicities prompted efforts to unravel immune and non-immune factors regulating the responses to ICT. This review highlights the biology of anti-tumor immunity underlying response and resistance to ICT, discusses efforts to address the current challenges with ICT, and outlines strategies to guide the development of subsequent clinical trials and combinatorial efforts with ICT.
科研通智能强力驱动
Strongly Powered by AbleSci AI